Clinical Trial Update: Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia [Phase 3]

View source ↗

Summary

Pfizer-sponsored Phase 3 trial evaluating PN-152,243 and PN-196,444 for the prevention of thrombocytopenia in sarcoma patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcoma

Drugs mentioned

• PN-152,243
• PN-196,444

Snippet

Sponsor: Pfizer | Conditions: Sarcoma | Phase 3 | Status: COMPLETED